These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30760052)

  • 1. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
    Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
    Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
    Gonçalves N; Simões AT; Cunha RA; de Almeida LP
    Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
    PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
    Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
    Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
    Simões AT; Carmona V; Duarte-Neves J; Cunha-Santos J; Pereira de Almeida L
    Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12748. PubMed ID: 34273111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
    Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L
    Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nóbrega C; Carmo-Silva S; Albuquerque D; Vasconcelos-Ferreira A; Vijayakumar UG; Mendonça L; Hirai H; de Almeida LP
    Brain; 2015 Dec; 138(Pt 12):3537-54. PubMed ID: 26490332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease.
    Duarte-Neves J; Gonçalves N; Cunha-Santos J; Simões AT; den Dunnen WF; Hirai H; Kügler S; Cavadas C; Pereira de Almeida L
    Hum Mol Genet; 2015 Oct; 24(19):5451-63. PubMed ID: 26220979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
    Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP
    Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Déglon N; de Almeida LP
    PLoS One; 2014; 9(8):e100086. PubMed ID: 25144231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Conceição M; Déglon N; de Almeida LP
    Cerebellum; 2013 Aug; 12(4):441-55. PubMed ID: 23242710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype.
    Conceição M; Mendonça L; Nóbrega C; Gomes C; Costa P; Hirai H; Moreira JN; Lima MC; Manjunath N; Pereira de Almeida L
    Biomaterials; 2016 Mar; 82():124-37. PubMed ID: 26757259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
    Raj K; Akundi RS
    Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
    Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular vesicle-based delivery of silencing sequences for the treatment of Machado-Joseph disease/spinocerebellar ataxia type 3.
    Rufino-Ramos D; Albuquerque PR; Leandro K; Carmona V; Martins IM; Fernandes R; Henriques C; Lobo D; Faro R; Perfeito R; Mendonça LS; Pereira D; Gomes CM; Nobre RJ; Pereira de Almeida L
    Mol Ther; 2023 May; 31(5):1275-1292. PubMed ID: 37025062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.
    Simões AT; Gonçalves N; Koeppen A; Déglon N; Kügler S; Duarte CB; Pereira de Almeida L
    Brain; 2012 Aug; 135(Pt 8):2428-39. PubMed ID: 22843411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors.
    Fish RJ; Kruithof EK
    BMC Mol Biol; 2004 Aug; 5():9. PubMed ID: 15291968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.
    Oliveira Miranda C; Marcelo A; Silva TP; Barata J; Vasconcelos-Ferreira A; Pereira D; Nóbrega C; Duarte S; Barros I; Alves J; Sereno J; Petrella LI; Castelhano J; Paiva VH; Rodrigues-Santos P; Alves V; Nunes-Correia I; Nobre RJ; Gomes C; Castelo-Branco M; Pereira de Almeida L
    Mol Ther; 2018 Sep; 26(9):2131-2151. PubMed ID: 30087083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.
    Colomer Gould VF
    NeuroRx; 2005 Jul; 2(3):480-3. PubMed ID: 16389311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.